Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Chronic Heart Failure

Free Subscription Articles published in Circulation Retrieve available abstracts of 198 articles: HTML format

Single Articles

November 2021
1. BARALLOBRE-BARREIRO J, Radovits T, Fava M, Mayr U, et al
   The Extracellular Matrix in Heart Failure: The Role of Adamts5 In Proteoglycan Remodelling.
   Circulation. 2021 Nov 22. doi: 10.1161/CIRCULATIONAHA.121.055732.
   PubMed     Abstract available
   
   
   
2. PFEFFER MA, Claggett B, Lewis EF, Granger CB, et al
   Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.
   Circulation. 2021 Nov 19. doi: 10.1161/CIRCULATIONAHA.121.057429.
   PubMed    
   
   
   
3. BUTLER J, Filippatos G, Siddiqi TJ, Brueckmann M, et al
   Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
   Circulation. 2021 Nov 15. doi: 10.1161/CIRCULATIONAHA.121.057812.
   PubMed     Abstract available
   
   
   
4. FILIPPATOS G, Anker SD, Agarwal R, Ruilope LM, et al
   Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial.
   Circulation. 2021 Nov 13. doi: 10.1161/CIRCULATIONAHA.121.057983.
   PubMed     Abstract available
   
   
   
5. BURRAGE MK, Hundertmark M, Valkovic L, Watson WD, et al
   Energetic Basis for Exercise-Induced Pulmonary Congestion in Heart Failure With Preserved Ejection Fraction.
   Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.054858.
   PubMed    
   
   
   
6. MENTIAS A, Desai MY, Vaughan-Sarrazin MS, Rao S, et al
   Community-level Economic Distress, Race, and Risk of Adverse Outcomes Following Heart Failure Hospitalization among Medicare Beneficiaries.
   Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.057756.
   PubMed     Abstract available
   
   
   
7. BERG DD, Docherty KF, Sattar N, Jarolim P, et al
   Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
   Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.057852.
   PubMed     Abstract available
   
   
   
8. HO JE, Nguyen C, Lewis GD
   Unmasking Nonpreserved Heart Structure, Function, and Energetics in Heart Failure With Preserved Ejection Fraction With Magnetic Resonance Imaging Coupled With Exercise.
   Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.056974.
   PubMed    
   
   
   October 2021
9. YAZAKI Y, Nakamura M, Iijima R, Yasuda S, et al
   Clinical Outcomes of Rivaroxaban Monotherapy in Heart Failure Patients With Atrial Fibrillation and Stable Coronary Disease: Insights From the AFIRE Trial.
   Circulation. 2021;144:1449-1451.
   PubMed    
   
   
   
10. HAN YS, Arteaga GM, Sharain K, Sieck GC, et al
    Rat Model of Heart Failure With Preserved Ejection Fraction: Changes in Contractile Proteins Regulating Ca(2+) Cycling and Vascular Reactivity.
    Circulation. 2021;144:1355-1358.
    PubMed    
    
    
    
11. HAJJAR RJ, Leopold JA
    Inflammation and Heart Failure: Friend or Foe?
    Circulation. 2021;144:1241-1243.
    PubMed    
    
    
    September 2021
12. 
    Correction to: Letter by Ren et al Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;144:e212.
    PubMed    
    
    
    
13. HIEDA M, Sarma S, Hearon CM Jr, MacNamara JP, et al
    One-Year Committed Exercise Training Reverses Abnormal Left Ventricular Myocardial Stiffness in Patients With Stage B Heart Failure With Preserved Ejection Fraction.
    Circulation. 2021;144:934-946.
    PubMed     Abstract available
    
    
    
14. MORRIS AA, Khazanie P, Drazner MH, Albert NM, et al
    Guidance for Timely and Appropriate Referral of Patients With Advanced Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2021 Sep 10:CIR0000000000001016. doi: 10.1161/CIR.0000000000001016.
    PubMed     Abstract available
    
    
    
15. DANIELS MJ, Fusi L, Semsarian C, Naidu SS, et al
    Myosin Modulation in Hypertrophic Cardiomyopathy and Systolic Heart Failure: Getting Inside the Engine.
    Circulation. 2021;144:759-762.
    PubMed    
    
    
    August 2021
16. PACKER M, Butler J, Zannad F, Filippatos G, et al
    Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and a Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
    Circulation. 2021 Aug 29. doi: 10.1161/CIRCULATIONAHA.121.056824.
    PubMed     Abstract available
    
    
    
17. PACKER M, Zannad F, Anker SD
    Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials.
    Circulation. 2021 Aug 29. doi: 10.1161/CIRCULATIONAHA.121.056657.
    PubMed    
    
    
    
18. EZEKOWITZ JA, Zheng Y, Cohen-Solal A, Melenovsky V, et al
    Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA).
    Circulation. 2021 Aug 25. doi: 10.1161/CIRCULATIONAHA.121.056797.
    PubMed     Abstract available
    
    
    
19. ANKER SD, Ponikowski P, Wanner C, Pfarr E, et al
    Kidney Function After Initiation and Discontinuation of Empagliflozin in Heart Failure Patients With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
    Circulation. 2021 Aug 16. doi: 10.1161/CIRCULATIONAHA.121.054669.
    PubMed    
    
    
    
20. KORF-KLINGEBIEL M, Reboll MR, Polten F, Weber N, et al
    Myeloid-Derived Growth Factor Protects Against Pressure Overload-Induced Heart Failure by Preserving Sarco/Endoplasmic Reticulum Ca(2+)-ATPase Expression in Cardiomyocytes.
    Circulation. 2021 Aug 10. doi: 10.1161/CIRCULATIONAHA.120.053365.
    PubMed     Abstract available
    
    
    July 2021
21. RILLIG A, Magnussen C, Ozga AK, Suling A, et al
    Early Rhythm Control Therapy in Patients with Atrial Fibrillation and Heart Failure.
    Circulation. 2021 Jul 30. doi: 10.1161/CIRCULATIONAHA.121.056323.
    PubMed     Abstract available
    
    
    
22. SAWICKI KT, Ardehali H
    Intravenous Iron Therapy in Heart Failure With Reduced Ejection Fraction: Tackling the Deficiency.
    Circulation. 2021;144:253-255.
    PubMed    
    
    
    
23. LEE MMY, McMurray JJV, Jhund PS, Petrie MC, et al
    Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".
    Circulation. 2021;144:e40.
    PubMed    
    
    
    
24. SINGH JS, Struthers AD, Lang CC
    Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".
    Circulation. 2021;144:e38-e39.
    PubMed    
    
    
    
25. FELKER GM, Butler J, Ibrahim NE, Pina IL, et al
    Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF.
    Circulation. 2021;144:180-182.
    PubMed    
    
    
    June 2021
26. BREATHETT K, Knapp SM, Carnes M, Calhoun E, et al
    Imbalance in Heart Transplant to Heart Failure Mortality Ratio Among African American, Hispanic, and White Patients.
    Circulation. 2021;143:2412-2414.
    PubMed    
    
    
    
27. MORRIS AA, Testani JM, Butler J
    Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities.
    Circulation. 2021;143:2329-2331.
    PubMed    
    
    
    
28. 
    Correction to: Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction.
    Circulation. 2021;143:e1027.
    PubMed    
    
    
    
29. FELKER GM, Butler J, Januzzi JL Jr, Desai AS, et al
    Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study.
    Circulation. 2021;143:2316-2318.
    PubMed    
    
    
    
30. BIRKS EJ, Rame JE, Cunningham C, Drakos SG, et al
    Response by Birks et al to Letters Regarding Article, "Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results".
    Circulation. 2021;143:e1017-e1018.
    PubMed    
    
    
    
31. JENSEN J, Omar M, Kistorp C, Tuxen C, et al
    Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).
    Circulation. 2021;143:2208-2210.
    PubMed    
    
    
    
32. MEHMOOD M
    Letter by Mehmood Regarding Article, "Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results".
    Circulation. 2021;143:e1014.
    PubMed    
    
    
    
33. MOAYEDI Y, Runeckles K, Posada JD
    Letter by Moayedi et al Regarding Article, "Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results".
    Circulation. 2021;143:e1015-e1016.
    PubMed    
    
    
    May 2021
34. KAR S, Mack MJ, Lindenfeld J, Abraham WT, et al
    Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure: The COAPT Trial.
    Circulation. 2021 May 27. doi: 10.1161/CIRCULATIONAHA.120.053061.
    PubMed     Abstract available
    
    
    
35. LOPES RD, Alexander KP, Hochman JS, Maron DJ, et al
    Response by Lopes et al to Letter Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial".
    Circulation. 2021;143:e961-e962.
    PubMed    
    
    
    
36. MORGAN H, Clayton T, Perera D
    Letter by Morgan et al Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial".
    Circulation. 2021;143:e959-e960.
    PubMed    
    
    
    
37. CARLEY AN, Maurya SK, Fasano M, Wang Y, et al
    Short-Chain Fatty Acids Outpace Ketone Oxidation in the Failing Heart.
    Circulation. 2021;143:1797-1808.
    PubMed     Abstract available
    
    
    April 2021
38. JOHANSSON I, Joseph P, Balasubramanian K, McMurray JJV, et al
    Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23,000 Patients from 40 Countries.
    Circulation. 2021 Apr 28. doi: 10.1161/CIRCULATIONAHA.120.050850.
    PubMed     Abstract available
    
    
    
39. 
    Correction to: Excessive O-GlcNAcylation Causes Heart Failure and Sudden Death.
    Circulation. 2021;143:e892.
    PubMed    
    
    
    
40. KANEKO H, Yano Y, Itoh H, Morita K, et al
    Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline with Risk of Heart Failure and Atrial Fibrillation.
    Circulation. 2021 Apr 22. doi: 10.1161/CIRCULATIONAHA.120.052624.
    PubMed     Abstract available
    
    
    
41. SEGAR MW, Jaeger BC, Patel KV, Nambi V, et al
    Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multi-Cohort Analysis.
    Circulation. 2021 Apr 13. doi: 10.1161/CIRCULATIONAHA.120.053134.
    PubMed     Abstract available
    
    
    
42. JHUND PS, Ponikowski P, Docherty KF, Gasparyan SB, et al
    Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure with Reduced Ejection Fraction: An Analysis of DAPA-HF.
    Circulation. 2021 Apr 9. doi: 10.1161/CIRCULATIONAHA.121.053659.
    PubMed     Abstract available
    
    
    
43. ROSENFELD LE, Enriquez AD
    The Cabana Trial and Heart Failure: Some Sun and Some Shade.
    Circulation. 2021;143:1391-1393.
    PubMed    
    
    
    March 2021
44. LOOMBA RS, Villarreal EG, Flores S
    Letter by Loomba et al Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;143:e755-e756.
    PubMed    
    
    
    
45. NAVARRO CASTELLANOS I, Dahdah N
    Letter by Navarro Castellanos and Dahdah Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;143:e759-e760.
    PubMed    
    
    
    
46. CARDENAS SURI H, Jimomila Bening D
    Letter by Cardenas Suri and Jimomila Bening Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;143:e757-e758.
    PubMed    
    
    
    
47. REN C, Qian M, Han C
    Letter by Ren et al Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;143:e761-e762.
    PubMed    
    
    
    
48. YU H, Zhang F, Yan P, Zhang S, et al
    LARP7 Protects Against Heart Failure by Enhancing Mitochondrial Biogenesis.
    Circulation. 2021 Mar 5. doi: 10.1161/CIRCULATIONAHA.120.050812.
    PubMed     Abstract available
    
    
    February 2021
49. UMAPATHI P, Banerjee PS, Zachara NE, Abrol N, et al
    Excessive O - GlcNAcylation Causes Heart Failure and Sudden Death.
    Circulation. 2021 Feb 17. doi: 10.1161/CIRCULATIONAHA.120.051911.
    PubMed     Abstract available
    
    
    
50. PACKER DL, Piccini JP, Monahan KH, Al-Khalidi HR, et al
    Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results from the CABANA Trial.
    Circulation. 2021 Feb 8. doi: 10.1161/CIRCULATIONAHA.120.050991.
    PubMed     Abstract available
    
    
    
51. NASSIF ME, Qintar M, Windsor SL, Jermyn R, et al
    Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results from EMpagliflozin Evaluation By MeasuRing ImpAct on HemodynamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Trial.
    Circulation. 2021 Feb 8. doi: 10.1161/CIRCULATIONAHA.120.052503.
    PubMed     Abstract available
    
    
    January 2021
52. 
    Correction to: Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from EMPEROR-Reduced.
    Circulation. 2021;143:e29.
    PubMed    
    
    
    
53. 
    Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
    Circulation. 2021;143:e30.
    PubMed    
    
    
    
54. KOSIBOROD M
    Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.
    Circulation. 2021;143:350-353.
    PubMed    
    
    
    
55. CARNICELLI AP, Mentz RJ
    Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: The Heart and Kidney Working Better Together.
    Circulation. 2021;143:322-325.
    PubMed    
    
    
    
56. HANG PZ, Zhao J
    Letter by Hang and Zhao Regarding Article, "Cardiac Overexpression of PDE4B Blunts beta-Adrenergic Response and Maladaptive Remodeling in Heart Failure".
    Circulation. 2021;143:e24-e25.
    PubMed    
    
    
    
57. VANDECASTEELE G, Mika D, Margaria JP, Ghigo A, et al
    Response by Vandecasteele et al to Letter Regarding Article, "Cardiac Overexpression of PDE4B Blunts beta-Adrenergic Response and Maladaptive Remodeling in Heart Failure".
    Circulation. 2021;143:e26-e27.
    PubMed    
    
    
    
58. BACKHAUS SJ, Lange T, George EF, Hellenkamp K, et al
    Exercise-Stress Real-time Cardiac Magnetic Resonance Imaging for Non-Invasive Characterisation of Heart Failure with Preserved Ejection Fraction: The HFpEF Stress Trial.
    Circulation. 2021 Jan 21. doi: 10.1161/CIRCULATIONAHA.120.051542.
    PubMed     Abstract available
    
    
    
59. CHURCHILL TW, Li SX, Curreri L, Zern EK, et al
    Evaluation of 2 Existing Diagnostic Scores for Heart Failure With Preserved Ejection Fraction Against a Comprehensively Phenotyped Cohort.
    Circulation. 2021;143:289-291.
    PubMed    
    
    
    
60. PINCKARD KM, Shettigar VK, Wright KR, Abay E, et al
    A Novel Endocrine Role for the BAT-Released Lipokine 12,13-diHOME to Mediate Cardiac Function.
    Circulation. 2021;143:145-159.
    PubMed     Abstract available
    
    
    December 2020
61. MCMURRAY JJV, Packer M
    How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine.
    Circulation. 2020 Dec 30. doi: 10.1161/CIRCULATIONAHA.120.052926.
    PubMed    
    
    
    
62. ZANNAD F, Cowie MR
    VERTIS-CV: More Evidence That Sodium Glucose Cotransporter 2 Inhibition Brings Rapid and Sustained Heart Failure Benefit.
    Circulation. 2020;142:2216-2218.
    PubMed    
    
    
    November 2020
63. EZEKOWITZ JA, Savu A, Welsh RC, McAlister FA, et al
    Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure?
    Circulation. 2020 Nov 30. doi: 10.1161/CIRCULATIONAHA.120.048015.
    PubMed    
    
    
    
64. SARMA S, Howden E, Lawley J, Samels M, et al
    Central Command and the Regulation of Exercise Heart Rate Response in Heart Failure with Preserved Ejection Fraction.
    Circulation. 2020 Nov 18. doi: 10.1161/CIRCULATIONAHA.120.048338.
    PubMed     Abstract available
    
    
    
65. ALLEN LA, Venechuk G, McIlvennan CK, Page Ii RL, et al
    An Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure with Reduced Ejection Fraction: The EPIC-HF Trial.
    Circulation. 2020 Nov 17. doi: 10.1161/CIRCULATIONAHA.120.051863.
    PubMed     Abstract available
    
    
    
66. 
    Correction to: Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
    Circulation. 2020;142:e369.
    PubMed    
    
    
    
67. LI X, Xue Q, Wang M, Zhou T, et al
    Adherence to a Healthy Sleep Pattern and Incident Heart Failure: A Prospective Study of 408802 UK Biobank Participants.
    Circulation. 2020 Nov 16. doi: 10.1161/CIRCULATIONAHA.120.050792.
    PubMed    
    
    
    
68. LEE MMY, Brooksbank KJM, Wetherall K, Mangion K, et al
    Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
    Circulation. 2020 Nov 13. doi: 10.1161/CIRCULATIONAHA.120.052186.
    PubMed     Abstract available
    
    
    
69. ANKER SD, Butler J, Filippatos G, Khan MS, et al
    Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial.
    Circulation. 2020 Nov 11. doi: 10.1161/CIRCULATIONAHA.120.051824.
    PubMed     Abstract available
    
    
    
70. GIERULA J, Lowry JE, Paton MF, Cole CA, et al
    Response by Gierula et al to Letter Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study".
    Circulation. 2020;142:e319-e320.
    PubMed    
    
    
    
71. LAU CP, Tse HF
    Letter by Lau and Tse Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study".
    Circulation. 2020;142:e317-e318.
    PubMed    
    
    
    
72. ALBERT CL, Carmona-Rubio AE, Weiss AJ, Procop GG, et al
    The Enemy Within: Sudden-Onset Reversible Cardiogenic Shock With Biopsy-Proven Cardiac Myocyte Infection by Severe Acute Respiratory Syndrome Coronavirus 2.
    Circulation. 2020;142:1865-1870.
    PubMed    
    
    
    
73. PATEL KV, Bahnson JL, Gaussoin SA, Johnson KC, et al
    Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of Heart Failure and Myocardial Infarction in Type 2 Diabetes: Findings From the Look AHEAD Trial.
    Circulation. 2020 Nov 9. doi: 10.1161/CIRCULATIONAHA.120.050941.
    PubMed    
    
    
    
74. 
    Correction to: Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Circulation. 2020;142:e316.
    PubMed    
    
    
    
75. HO JE, Redfield MM, Lewis GD, Paulus WJ, et al
    Deliberating the Diagnostic Dilemma of Heart Failure With Preserved Ejection Fraction.
    Circulation. 2020;142:1770-1780.
    PubMed     Abstract available
    
    
    October 2020
76. HAHN VS, Knutsdottir H, Luo X, Bedi K, et al
    Myocardial Gene Expression Signatures in Human Heart Failure with Preserved Ejection Fraction.
    Circulation. 2020 Oct 29. doi: 10.1161/CIRCULATIONAHA.120.050498.
    PubMed     Abstract available
    
    
    
77. BIRKS EJ, Drakos SG, Patel SR, Lowes BD, et al
    A Prospective Multicentre Study of Myocardial Recovery Using Left Ventricular Assist Devices (REmission from Stage D Heart Failure: RESTAGE-HF): Medium Term and Primary Endpoint Results.
    Circulation. 2020 Oct 26. doi: 10.1161/CIRCULATIONAHA.120.046415.
    PubMed     Abstract available
    
    
    
78. ZANNAD F, Ferreira JP, Pocock SJ, Zeller C, et al
    Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial.
    Circulation. 2020 Oct 23. doi: 10.1161/CIRCULATIONAHA.120.051685.
    PubMed     Abstract available
    
    
    
79. PACKER M, Anker SD, Butler J, Filippatos GS, et al
    Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
    Circulation. 2020 Oct 21. doi: 10.1161/CIRCULATIONAHA.120.051783.
    PubMed     Abstract available
    
    
    
80. THIBODEAU JT, Gorodeski EZ
    Telehealth for Uptitration of Guideline-Directed Medical Therapy in Heart Failure.
    Circulation. 2020;142:1507-1509.
    PubMed    
    
    
    
81. 
    Correction to: Prioritizing Candidates of Post-Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics.
    Circulation. 2020;142:e234.
    PubMed    
    
    
    
82. 
    Correction to: Initial Invasive versus Conservative Management of Stable Ischemic Heart Disease Patients with a History of Heart Failure or Left Ventricular Dysfunction: Insights from the ISCHEMIA Trial.
    Circulation. 2020;142:e236.
    PubMed    
    
    
    
83. JHUND PS, Solomon SD, Docherty KF, Heerspink HJL, et al
    Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF.
    Circulation. 2020 Oct 12. doi: 10.1161/CIRCULATIONAHA.120.050391.
    PubMed     Abstract available
    
    
    
84. SANDERS-VAN WIJK S, Tromp J, Beussink-Nelson L, Hage C, et al
    Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure with Preserved Ejection Fraction: Results from the PROMIS-HFpEF Study.
    Circulation. 2020 Oct 9. doi: 10.1161/CIRCULATIONAHA.120.045810.
    PubMed     Abstract available
    
    
    
85. COSENTINO F, Cannon CP, Cherney DZI, Masiukiewicz U, et al
    Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Circulation. 2020 Oct 7. doi: 10.1161/CIRCULATIONAHA.120.050255.
    PubMed     Abstract available
    
    
    September 2020
86. TOBE SW, Poon S
    Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes.
    Circulation. 2020;142:1246-1248.
    PubMed    
    
    
    
87. KHAN MS, Fonarow GC, McGuire DK, Hernandez AF, et al
    Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
    Circulation. 2020;142:1205-1218.
    PubMed     Abstract available
    
    
    
88. LI J, Tan Y, Passariello CL, Martinez EC, et al
    Signalosome-Regulated SRF Phosphorylation Determining Myocyte Growth in Width versus Length as a Therapeutic Target for Heart Failure.
    Circulation. 2020 Sep 16. doi: 10.1161/CIRCULATIONAHA.119.044805.
    PubMed     Abstract available
    
    
    
89. GRODIN JL, Tang WHW
    Sodium-Glucose Cotransporter-2 Inhibitors and Loop Diuretics for Heart Failure: Priming the Natriuretic and Metabolic Reserve of the Kidney.
    Circulation. 2020;142:1055-1058.
    PubMed    
    
    
    
90. PARCHA V, Patel N, Kalra R, Arora G, et al
    Racial Differences in Serial NT-proBNP Levels in Heart Failure Management: Insights From the GUIDE-IT Trial.
    Circulation. 2020;142:1018-1020.
    PubMed    
    
    
    
91. VERBRUGGE FH, Guazzi M, Testani JM, Borlaug BA, et al
    Altered Hemodynamics and End-Organ Damage in Heart Failure: Impact on the Lung and Kidney.
    Circulation. 2020;142:998-1012.
    PubMed     Abstract available
    
    
    
92. CHAN MY, Efthymios M, Tan SH, Pickering JW, et al
    Prioritizing Candidates of Post-Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics.
    Circulation. 2020 Sep 4. doi: 10.1161/CIRCULATIONAHA.119.045158.
    PubMed     Abstract available
    
    
    
93. DOCHERTY KF, Jhund PS, Anand I, Bengtsson O, et al
    Effect of Dapagliflozin on Outpatient Worsening of Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.
    Circulation. 2020 Sep 4. doi: 10.1161/CIRCULATIONAHA.120.047480.
    PubMed     Abstract available
    
    
    
94. DURSTENFELD MS, Hsue PY
    An Unusual, Reversible Cause of Acute High-Output Heart Failure Complicated by Refractory Shock.
    Circulation. 2020;142:901-905.
    PubMed    
    
    
    August 2020
95. MORDI NA, Mordi IR, Singh JS, McCrimmon RJ, et al
    Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Circulation. 2020 Aug 29. doi: 10.1161/CIRCULATIONAHA.120.048739.
    PubMed     Abstract available
    
    
    
96. LOPES RD, Alexander KP, Stevens SR, Reynolds HR, et al
    Initial Invasive versus Conservative Management of Stable Ischemic Heart Disease Patients with a History of Heart Failure or Left Ventricular Dysfunction: Insights from the ISCHEMIA Trial.
    Circulation. 2020 Aug 29. doi: 10.1161/CIRCULATIONAHA.120.050304.
    PubMed     Abstract available
    
    
    
97. MC CAUSLAND FR, Lefkowitz MP, Claggett B, Anavekar NS, et al
    Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure with Preserved Ejection Fraction.
    Circulation. 2020 Aug 17. doi: 10.1161/CIRCULATIONAHA.120.047643.
    PubMed     Abstract available
    
    
    
98. CHEN F, Chen ZQ, Zhu JJ
    Letter by Chen et al Regarding Article, "Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study".
    Circulation. 2020;142:e67-e68.
    PubMed    
    
    
    
99. LEWIS AA, de Lemos JA
    Response by Lewis and de Lemos to Letter Regarding Article, "Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study".
    Circulation. 2020;142:e69-e70.
    PubMed    
    
    
    
100. SIMPSON JM, Newburger JW
     Multisystem Inflammatory Syndrome in Children in Association With COVID-19.
     Circulation. 2020;142:437-440.
     PubMed    
     
     
     July 2020
101. OMURA J, Habbout K, Shimauchi T, Wu WH, et al
     Identification of The Long Non-Coding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension.
     Circulation. 2020 Jul 23. doi: 10.1161/CIRCULATIONAHA.120.047626.
     PubMed     Abstract available
     
     
     
102. JACKSON AM, Dewan P, Anand IS, Belohlavek J, et al
     Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF.
     Circulation. 2020 Jul 16. doi: 10.1161/CIRCULATIONAHA.120.047077.
     PubMed     Abstract available
     
     
     
103. JACKSON AM, Jhund PS, Solomon SD, McMurray JJV, et al
     Response by Jackson et al to Letter Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".
     Circulation. 2020;142:e5-e6.
     PubMed    
     
     
     
104. WU K, Zhao S
     Letter by Wu and Zhao Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".
     Circulation. 2020;142:e3-e4.
     PubMed    
     
     
     June 2020
105. MOAZZAMI K, Wittbrodt MT, Lima BB, Nye JA, et al
     Higher Activation of the Rostromedial Prefrontal Cortex during Mental Stress Predicts Major Cardiovascular Disease Events in Individuals with Coronary Artery Disease.
     Circulation. 2020 Jun 11. doi: 10.1161/CIRCULATIONAHA.119.044442.
     PubMed     Abstract available
     
     
     
106. AL-KHATIB SM, Benjamin EJ, Albert CM, Alonso A, et al
     Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop.
     Circulation. 2020;141:1915-1926.
     PubMed     Abstract available
     
     
     
107. PANDEY A, Vaduganathan M, Arora S, Qamar A, et al
     Temporal Trends in Prevalence & Prognostic Implications of Comorbidities Among Patients with Acute Decompensated Heart Failure: The ARIC Study Community Surveillance.
     Circulation. 2020 Jun 3. doi: 10.1161/CIRCULATIONAHA.120.047019.
     PubMed     Abstract available
     
     
     
108. HONG YS, Longchamps RJ, Zhao D, Castellani CA, et al
     Mitochondrial DNA Copy Number and Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study.
     Circulation. 2020;141:1823-1825.
     PubMed    
     
     
     
109. SELVARAJ S, Kelly DP, Margulies KB
     Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure.
     Circulation. 2020;141:1800-1812.
     PubMed     Abstract available
     
     
     
110. LEE H, Yano Y, Cho SMJ, Park JH, et al
     Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults.
     Circulation. 2020;141:1778-1786.
     PubMed     Abstract available
     
     
     May 2020
111. SARMA S, Levine BD
     Response by Sarma and Levine to Letter Regarding Article, "Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction".
     Circulation. 2020;141:e822.
     PubMed    
     
     
     
112. KOMAMURA K
     Letter by Komamura Regarding Article, "Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction".
     Circulation. 2020;141:e819.
     PubMed    
     
     
     
113. BELKIN M, Michou E, Mueller C
     Letter by Belkin et al Regarding Article, "Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction".
     Circulation. 2020;141:e820-e821.
     PubMed    
     
     
     
114. NWABUO CC, Rana JS
     Letter by Nwabuo and Rana Regarding Article, "Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction".
     Circulation. 2020;141:e817-e818.
     PubMed    
     
     
     
115. BELHADJER Z, Meot M, Bajolle F, Khraiche D, et al
     Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic.
     Circulation. 2020 May 17. doi: 10.1161/CIRCULATIONAHA.120.048360.
     PubMed     Abstract available
     
     
     
116. GRIFFIN M, Rao VS, Ivey-Miranda J, Fleming J, et al
     Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects.
     Circulation. 2020 May 15. doi: 10.1161/CIRCULATIONAHA.120.045691.
     PubMed     Abstract available
     
     
     
117. 
     Correction to: Combined Ventricular Systolic and Arterial Stiffening in Patients With Heart Failure and Preserved Ejection Fraction: Implications for Systolic and Diastolic Reserve Limitations.
     Circulation. 2020;141:e809.
     PubMed    
     
     
     April 2020
118. BADOLIA R, Ramadurai DKA, Abel ED, Ferrin P, et al
     The Role of Non-Glycolytic Glucose Metabolism in Myocardial Recovery upon Mechanical Unloading and Circulatory Support in Chronic Heart Failure.
     Circulation. 2020 Apr 30. doi: 10.1161/CIRCULATIONAHA.119.044452.
     PubMed     Abstract available
     
     
     
119. KITKO L, McIlvennan CK, Bidwell JT, Dionne-Odom JN, et al
     Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association.
     Circulation. 2020 Apr 30:CIR0000000000000768. doi: 10.1161/CIR.0000000000000768.
     PubMed     Abstract available
     
     
     
120. WHITE-WILLIAMS C, Rossi LP, Bittner VA, Driscoll A, et al
     Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association.
     Circulation. 2020 Apr 30:CIR0000000000000767. doi: 10.1161/CIR.0000000000000767.
     PubMed     Abstract available
     
     
     
121. ARMSTRONG PW
     Enhancing Cardiovascular Care: Global Collaboration Is How It Happens.
     Circulation. 2020;141:1357-1359.
     PubMed    
     
     
     
122. GIERULA J, Lowry JE, Paton MF, Cole CA, et al
     Personalised Rate-Response Programming Improves Exercise Tolerance After Six Months in People with Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study.
     Circulation. 2020 Apr 17. doi: 10.1161/CIRCULATIONAHA.119.045066.
     PubMed     Abstract available
     
     
     
123. KARAM S, Margaria JP, Bourcier A, Mika D, et al
     Cardiac Overexpression of PDE4B Blunts beta-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
     Circulation. 2020 Apr 8. doi: 10.1161/CIRCULATIONAHA.119.042573.
     PubMed     Abstract available
     
     
     
124. FRIED JA, Ramasubbu K, Bhatt R, Topkara VK, et al
     The Variety of Cardiovascular Presentations of COVID-19.
     Circulation. 2020 Apr 3. doi: 10.1161/CIRCULATIONAHA.120.047164.
     PubMed    
     
     
     
125. CHIRINOS JA, Zhao L, Jia Y, Frej C, et al
     Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure.
     Circulation. 2020 Apr 2. doi: 10.1161/CIRCULATIONAHA.119.045323.
     PubMed     Abstract available
     
     
     March 2020
126. TOTO RD
     Leveraging the Peritoneum as a New Diuretic Strategy for Heart Failure.
     Circulation. 2020;141:1054-1056.
     PubMed    
     
     
     
127. SHAH SJ, Borlaug BA, Kitzman DW, McCulloch AD, et al
     Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary.
     Circulation. 2020;141:1001-1026.
     PubMed     Abstract available
     
     
     
128. LITTMANN L
     Letter by Littmann Regarding Article, "Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure R
     Circulation. 2020;141:e646-e647.
     PubMed    
     
     
     
129. SCHRAGE B, Linde C, Braunschweig F, Savarese G, et al
     Response by Schrage et al to Letter Regarding Article, "Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedis
     Circulation. 2020;141:e648-e649.
     PubMed    
     
     
     
130. CHARTON M, Flecher E, Leclercq C, Delmas C, et al
     Suicide Attempts Among LVAD Recipients: Real-Life Data From the ASSIST-ICD Study.
     Circulation. 2020;141:934-936.
     PubMed    
     
     
     
131. CAPORIZZO MA, Chen CY, Bedi K, Margulies KB, et al
     Microtubules Increase Diastolic Stiffness in Failing Human Cardiomyocytes and Myocardium.
     Circulation. 2020;141:902-915.
     PubMed     Abstract available
     
     
     
132. PANDEY A, Patel KV, Bahnson JL, Gaussoin SA, et al
     Association of Intensive Lifestyle Intervention, Fitness and Body Mass Index with Risk of Heart Failure in Overweight or Obese Adults with Type 2 Diabetes Mellitus: An Analysis from the Look AHEAD Trial.
     Circulation. 2020 Mar 5. doi: 10.1161/CIRCULATIONAHA.119.044865.
     PubMed     Abstract available
     
     
     
133. SCHIATTARELLA GG, Tong D, Hill JA
     Can HFpEF and HFrEF Coexist?
     Circulation. 2020;141:709-711.
     PubMed    
     
     
     February 2020
134. KUEHN BM
     Race May Influence Transplant Decision Making in Heart Failure: Studies Also Detail Disparities in Hypertension Diagnosis, Statin Prescribing.
     Circulation. 2020;141:694-695.
     PubMed    
     
     
     
135. ROSENKRANZ S, Howard LS, Gomberg-Maitland M, Hoeper MM, et al
     Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure.
     Circulation. 2020;141:678-693.
     PubMed     Abstract available
     
     
     
136. OMIYA S, Omori Y, Taneike M, Murakawa T, et al
     Cytokine mRNA Degradation in Cardiomyocytes Restrains Sterile Inflammation in Pressure-Overloaded Hearts.
     Circulation. 2020;141:667-677.
     PubMed     Abstract available
     
     
     
137. HILFIKER-KLEINER D, Konig T, Bauersachs J
     Natriuretic Peptide Receptor 1, a Novel Player in Peripartum Heart Failure.
     Circulation. 2020;141:589-591.
     PubMed    
     
     
     
138. KHOSROW-KHAVAR F, Filion KB, Bouganim N, Suissa S, et al
     Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
     Circulation. 2020;141:549-559.
     PubMed     Abstract available
     
     
     
139. KUEHN BM
     Biomarkers May Help Stratify Patient Heart Failure Risk, Guide Treatment.
     Circulation. 2020;141:399-400.
     PubMed    
     
     
     
140. BOZKURT B, Ezekowitz J
     Substance and Substrate: LVEF and Sex Subgroup Analyses of PARAGON-HF and PARADIGM-HF Trials.
     Circulation. 2020;141:362-366.
     PubMed    
     
     
     January 2020
141. BERGMARK BA, Bhatt DL, McGuire DK, Scirica BM, et al
     Response by Bergmark et al to Letter Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial".
     Circulation. 2020;141:e57-e58.
     PubMed    
     
     
     
142. MORDI IR, Mohan M, Lang CC
     Letter by Mordi et al Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial".
     Circulation. 2020;141:e55-e56.
     PubMed    
     
     
     
143. GOMES CPDC, Schroen B, Kuster GM, Robinson EL, et al
     Regulatory RNAs in Heart Failure.
     Circulation. 2020;141:313-328.
     PubMed     Abstract available
     
     
     
144. LEWIS AA, Ayers CR, Selvin E, Neeland I, et al
     Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multi-Cohort Study.
     Circulation. 2020 Jan 14. doi: 10.1161/CIRCULATIONAHA.119.043628.
     PubMed     Abstract available
     
     
     
145. HIEDA M, Sarma S, Hearon CM Jr, Dias KA, et al
     Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction.
     Circulation. 2020;141:115-123.
     PubMed     Abstract available
     
     
     
146. PATERSON DI, Wells G, Erthal F, Mielniczuk L, et al
     OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients with Non-Ischemic Heart Failure (IMAGE-HF 1B).
     Circulation. 2020 Jan 8. doi: 10.1161/CIRCULATIONAHA.119.043964.
     PubMed     Abstract available
     
     
     
147. PACKER M, Lam CSP, Lund LH, Redfield MM, et al
     Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy.
     Circulation. 2020;141:4-6.
     PubMed    
     
     
     
148. FAYSSOIL A
     Letter by Fayssoil Regarding Article, "Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection Fraction".
     Circulation. 2020;141:e1-e2.
     PubMed    
     
     
     December 2019
149. BUTLER J, Packer M, Greene SJ, Fiuzat M, et al
     Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.
     Circulation. 2019;140:2108-2118.
     PubMed     Abstract available
     
     
     November 2019
150. TONG D, Schiattarella GG, Jiang N, May HI, et al
     Female Sex Is Protective in a Preclinical Model of Heart Failure With Preserved Ejection Fraction.
     Circulation. 2019;140:1769-1771.
     PubMed    
     
     
     
151. SOLOMON SD, Vaduganathan M, Claggett BL, Packer M, et al
     Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
     Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044586.
     PubMed     Abstract available
     
     
     
152. MCMURRAY JJV, Jackson AM, Lam CSP, Redfield MM, et al
     Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF.
     Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044491.
     PubMed     Abstract available
     
     
     
153. KOSIBOROD MN, Jhund P, Docherty KF, Diez M, et al
     Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial.
     Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044138.
     PubMed     Abstract available
     
     
     
154. FELKER GM
     Building the Foundation for a New Era of Quadruple Therapy in Heart Failure.
     Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044578.
     PubMed     Abstract available
     
     
     
155. MARTINEZ FA, Serenelli M, Nicolau JC, Petrie MC, et al
     Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
     Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044133.
     PubMed    
     
     
     
156. DEHARO P, Bisson A, Herbert J, Lacour T, et al
     Impact of Sapien 3 Balloon-Expandable Versus Evolut R Self-Expandable Transcatheter Aortic Valve Implantation in Patients with Aortic Stenosis: Data from a Nationwide Analysis.
     Circulation. 2019 Nov 16. doi: 10.1161/CIRCULATIONAHA.119.043971.
     PubMed     Abstract available
     
     
     
157. ARNOTT C, Neal B
     Do GLP-1 Receptor Agonists Care if You Have Heart Failure?
     Circulation. 2019;140:1623-1625.
     PubMed    
     
     
     
158. JIA X, Sun W, Hoogeveen RC, Nambi V, et al
     Response by Jia et al to Letter Regarding Article, "High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study".
     Circulation. 2019;140:e772-e773.
     PubMed    
     
     
     
159. LI D, Cheng Y
     Letter by Li and Cheng Regarding Article, "High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study".
     Circulation. 2019;140:e770-e771.
     PubMed    
     
     
     
160. DJOUSSE L, Cook NR, Kim E, Bodar V, et al
     Supplementation with Vitamin D and/or Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization: VITAL-Heart Failure.
     Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044645.
     PubMed     Abstract available
     
     
     October 2019
161. MARTINI E, Kunderfranco P, Peano C, Carullo P, et al
     Single Cell Sequencing of Mouse Heart Immune Infiltrate in Pressure Overload-Driven Heart Failure Reveals Extent of Immune Activation.
     Circulation. 2019 Oct 30. doi: 10.1161/CIRCULATIONAHA.119.041694.
     PubMed     Abstract available
     
     
     
162. ELGHAZALY H, Hajiev S, Singh P
     Letter by Elghazaly et al Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
     Circulation. 2019;140:e738-e739.
     PubMed    
     
     
     
163. KATO ET, Sabatine MS, Wiviott SD
     Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
     Circulation. 2019;140:e740-e741.
     PubMed    
     
     
     
164. DRAZNER MH, Stevenson LW
     Relief and Prevention of Congestion in Heart Failure Enhance Quality and Length of Life.
     Circulation. 2019;140:1380-1382.
     PubMed    
     
     
     
165. TROMP J, Hage C, Ouwerkerk W, Sanders-van Wijk S, et al
     Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.
     Circulation. 2019;140:1359-1361.
     PubMed    
     
     
     
166. KUEHN BM
     Gut Microbes Role in Heart Failure Explored.
     Circulation. 2019;140:1217-1218.
     PubMed    
     
     
     
167. TIAN R, Colucci WS, Arany Z, Bachschmid MM, et al
     Unlocking the Secrets of Mitochondria in the Cardiovascular System: Path to a Cure in Heart Failure-A Report from the 2018 National Heart, Lung, and Blood Institute Workshop
     Circulation. 2019;140:1205-1216.
     PubMed     Abstract available
     
     
     September 2019
168. BARON SJ, Wang K, Arnold SV, Magnuson EA, et al
     Cost-Effectiveness of Transcatheter Mitral Valve Repair versus Medical Therapy in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial.
     Circulation. 2019 Sep 29. doi: 10.1161/CIRCULATIONAHA.119.043275.
     PubMed     Abstract available
     
     
     
169. BONOW RO, Mark DB, O'Gara PT
     Coapting Cost and Clinical Outcomes in Transcatheter Intervention for Secondary Mitral Regurgitation.
     Circulation. 2019 Sep 29. doi: 10.1161/CIRCULATIONAHA.119.043408.
     PubMed    
     
     
     
170. AUNG N, Vargas JD, Yang C, Cabrera CP, et al
     Genome-Wide Analysis of Left Ventricular Image-Derived Phenotypes Identifies Fourteen Loci Associated with Cardiac Morphogenesis and Heart Failure Development.
     Circulation. 2019 Sep 25. doi: 10.1161/CIRCULATIONAHA.119.041161.
     PubMed     Abstract available
     
     
     
171. FUDIM M, White J, Pagidipati NJ, Lokhnygina Y, et al
     Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
     Circulation. 2019 Sep 23. doi: 10.1161/CIRCULATIONAHA.119.041659.
     PubMed     Abstract available
     
     
     
172. KHAZANIE P, Drazner MH
     The Blurred Line between Gaming and Patient Advocacy: Heart Transplant Listing Decisions in the Modern Era.
     Circulation. 2019 Sep 18. doi: 10.1161/CIRCULATIONAHA.119.043034.
     PubMed    
     
     
     
173. AL-KHATIB SM, Kusumoto FM
     Implantable Cardioverter Defibrillators Have Stood the Test of Time!
     Circulation. 2019 Sep 3. doi: 10.1161/CIRCULATIONAHA.119.043354.
     PubMed    
     
     
     July 2019
174. FAN Q, Mao H, Angelini A, Coarfa C, et al
     Depletion of Endothelial Prolyl Hydroxylase Domain Protein 2 and 3 Promotes Cardiomyocyte Proliferation and Prevents Ventricular Failure Induced by Myocardial Infarction.
     Circulation. 2019;140:440-442.
     PubMed    
     
     
     
175. FELDMAN AM, Gerhard GS, Cheung JY
     Letter by Feldman et al Regarding Article, "Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery".
     Circulation. 2019;140:e5-e6.
     PubMed    
     
     
     
176. ARAGAM KG, Chaffin M, Ellinor PT, Kathiresan S, et al
     Response by Aragam et al to Letter Regarding Article, "Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery".
     Circulation. 2019;140:e7-e8.
     PubMed    
     
     
     June 2019
177. KRONLAGE M, Dewenter M, Grosso J, Fleming T, et al
     O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart from Failure.
     Circulation. 2019 Jun 14. doi: 10.1161/CIRCULATIONAHA.117.031942.
     PubMed     Abstract available
     
     
     
178. GOLDENBERG JR, Carley AN, Ji R, Zhang X, et al
     Preservation of Acyl Coenzyme A Attenuates Pathological and Metabolic Cardiac Remodeling Through Selective Lipid Trafficking.
     Circulation. 2019;139:2765-2777.
     PubMed     Abstract available
     
     
     May 2019
179. NYSTROM T, Sartipy U, Contardi A, Lind M, et al
     Glycated Hemoglobin A1c Levels in Type 1 Diabetes Mellitus and Outcomes After Myocardial Infarction.
     Circulation. 2019;139:2380-2382.
     PubMed    
     
     
     
180. SMITH GL, Eisner DA
     Calcium Buffering in the Heart in Health and Disease.
     Circulation. 2019;139:2358-2371.
     PubMed     Abstract available
     
     
     
181. ENRIQUEZ-SARANO M, Michelena HI, Grigioni F
     Treatment of Functional Mitral Regurgitation.
     Circulation. 2019;139:2289-2291.
     PubMed    
     
     
     
182. GOPINATHANNAIR R, Cornwell WK, Dukes JW, Ellis CR, et al
     Device Therapy and Arrhythmia Management in Left Ventricular Assist Device Recipients: A Scientific Statement From the American Heart Association.
     Circulation. 2019;139:e967-e989.
     PubMed     Abstract available
     
     
     April 2019
183. SANO M, Goto S
     Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.
     Circulation. 2019;139:1985-1987.
     PubMed    
     
     
     
184. RANGASWAMI J, Bhalla V, Blair JEA, Chang TI, et al
     Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association.
     Circulation. 2019;139:e840-e878.
     PubMed     Abstract available
     
     
     March 2019
185. FURTADO RHM, Bonaca MP, Raz I, Zelniker TA, et al
     Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial.
     Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.039996.
     PubMed     Abstract available
     
     
     
186. JUKEMA JW, Timal RJ, Rotmans JI, Hensen LCR, et al
     Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients: The Prospective Randomized Controlled ICD2 Trial.
     Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.039818.
     PubMed     Abstract available
     
     
     February 2019
187. SAHA P, Potiny P, Rigdon J, Morello M, et al
     Substantial Cardiovascular Morbidity in Adults with Lower-Complexity Congenital Heart Disease.
     Circulation. 2019 Feb 28. doi: 10.1161/CIRCULATIONAHA.118.037064.
     PubMed     Abstract available
     
     
     
188. RAWSHANI A, Rawshani A, Sattar N, Franzen S, et al
     Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes.
     Circulation. 2019 Feb 25. doi: 10.1161/CIRCULATIONAHA.118.037454.
     PubMed     Abstract available
     
     
     January 2019
189. MATHIYALAGAN P, Adamiak M, Mayourian J, Sassi Y, et al
     FTO-Dependent N(6)-Methyladenosine Regulates Cardiac Function During Remodeling and Repair.
     Circulation. 2019;139:518-532.
     PubMed     Abstract available
     
     
     
190. ANDERSEN S, Nielsen-Kudsk JE, Vonk Noordegraaf A, de Man FS, et al
     Right Ventricular Fibrosis.
     Circulation. 2019;139:269-285.
     PubMed     Abstract available
     
     
     December 2018
191. KANG DH, Park SJ, Shin SH, Hong GR, et al
     Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: The PRIME Study.
     Circulation. 2018 Dec 5. doi: 10.1161/CIRCULATIONAHA.118.037077.
     PubMed     Abstract available
     
     
     
192. DIDIER R, Eltchaninoff H, Donzeau-Gouge P, Chevreul K, et al
     Five-Year Clinical Outcome and Valve Durability After Transcatheter Aortic Valve Replacement in High-Risk Patients.
     Circulation. 2018;138:2597-2607.
     PubMed     Abstract available
     
     
     November 2018
193. THYGESEN K, Alpert JS, Jaffe AS, Chaitman BR, et al
     Fourth Universal Definition of Myocardial Infarction (2018).
     Circulation. 2018;138:e618-e651.
     PubMed    
     
     
     September 2018
194. DAWSON J
     Pioglitazone Use After Stroke.
     Circulation. 2018;138:1221-1223.
     PubMed    
     
     
     
195. COLOMBO PC, Mehra MR, Goldstein DJ, Estep JD, et al
     Comprehensive Analysis of Stroke in the LongTerm Cohort of the MOMENTUM 3 Study: A Randomized Controlled Trial of the HeartMate 3 Versus the HeartMate II Cardiac Pump.
     Circulation. 2018 Sep 17. doi: 10.1161/CIRCULATIONAHA.118.037231.
     PubMed     Abstract available
     
     
     August 2018
196. SARRIAS A, Bayes-Genis A
     Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?
     Circulation. 2018;138:551-553.
     PubMed    
     
     
     July 2018
197. SATTAR N, McGuire DK
     Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink.
     Circulation. 2018;138:7-9.
     PubMed    
     
     
     June 2018
198. SHARMA A, Hijazi Z, Andersson U, Al-Khatib SM, et al
     The Use of Biomarkers to Predict Specific Causes of Death in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial.
     Circulation. 2018 Jun 5. pii: CIRCULATIONAHA.118.034125.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: